
[ Thu, May 13th 2021 ]: WOPRAI
[ Thu, May 13th 2021 ]: WOPRAI
[ Thu, May 13th 2021 ]: WOPRAI
[ Thu, May 13th 2021 ]: WOPRAI

[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI
[ Wed, May 12th 2021 ]: WOPRAI

[ Tue, May 11th 2021 ]: WOPRAI
[ Tue, May 11th 2021 ]: WOPRAI
[ Tue, May 11th 2021 ]: WOPRAI
[ Tue, May 11th 2021 ]: WOPRAI
Sumant Kulkarni Maintained (ACAD) at Hold with Increased Target to $27 on, May 12th, 2021


🞛 This publication is a summary or evaluation of another publication
Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $26 to $27 on, May 12th, 2021.
Sumant has made no other calls on ACAD in the last 4 months.
There are 11 other peers that have a rating on ACAD. Out of the 11 peers that are also analyzing ACAD, 8 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrew Fein of "HC Wainwright & Co." Downgraded from Strong Buy to Hold and Decreased Target to $18 on, Wednesday, April 7th, 2021
- Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $21 on, Tuesday, April 6th, 2021
- Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Tuesday, April 6th, 2021
- Vamil Divan of "Mizuho" Downgraded from Strong Buy to Hold and Held Target at $25 on, Tuesday, April 6th, 2021
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold on, Wednesday, March 10th, 2021
- Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $35 on, Tuesday, March 9th, 2021
- Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $27 on, Tuesday, March 9th, 2021
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Tuesday, March 9th, 2021
These are the ratings of the 3 analyists that currently disagree with Sumant
- Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Increased Target to $29 on, Thursday, May 6th, 2021
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, April 5th, 2021
- Danielle Brill of "Raymond James" Downgraded from Strong Buy to Buy and Decreased Target to $35 on, Tuesday, March 9th, 2021